About Isofol
Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with new dosage regimens that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- February 19, 2025 - February 19, 2025
Year-end report 2024 - April 09, 2025 - April 11, 2025
Annual report 2024, published in week 15, April 2025 - May 21, 2025 - May 21, 2025
Interim report January-March 2025
Media – Lates pressreleases
Isofol appoints Roger Tell as Chief Medical Officer ahead of initiation of clinical study
GOTHENBURG, Sweden, February 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that Roger Tell has been appointed Chief Medical Officer…
Isofol announces the presentation of a post-hoc analysis of the phase III study AGENT at the 2025 ASCO GI symposium
GOTHENBURG, Sweden, January 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that an abstract of the post-hoc per-protocol analysis of…
Isofol and its partner Solasia plan to expand the upcoming clinical trial of arfolitixorin to Japan
GOTHENBURG, Sweden, December 18, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that its partner Solasia Pharma K.K. (Solasia) has made…